Atara Biotherapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGAtara Biotherapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 95), indicating clear outperformance against the broad market. Earnings contraction of 108% provides fundamental context to the price action. However, price is extended 20% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $10.45 | +4.15% | ABOVE |
| 50 SMA | $9.07 | +20.02% | ABOVE |
| 100 SMA | $7.06 | +54.14% | ABOVE |
| 150 SMA | $8.61 | +26.31% | ABOVE |
| 200 SMA | $9.93 | +9.52% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ATRA in an uptrend right now?
ATRA has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ATRA overbought or oversold?
ATRA's RSI (14) is 65. The stock is in neutral territory, neither overbought nor oversold.
Is ATRA outperforming the market?
ATRA has a Relative Strength (RS) Rating of 95 out of 99. Yes, ATRA is a market leader, outperforming 95% of all stocks over the past 12 months.
Where is ATRA in its 52-week range?
ATRA is trading at $10.88, which is 57% of its 52-week high ($19.14) and 46% above its 52-week low ($3.92).
How volatile is ATRA?
ATRA has a Beta of 1.36 and 52-week volatility of 144%. It's more volatile than the S&P 500 - expect bigger swings.